Related content

Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 10-19

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 754-756

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effective Induction Therapy with Subcutaneous Administration of Bortezomib for Newly Diagnosed POEMS Syndrome: A Case Report and a Review of the Literature

By  

Acta Haematologica, Vol. 129, Iss. 2, 2012-11 ,pp. : 101-105

Karger

Access to resources Recommend Favorite

An Acceptable Incidence of Infusion Site Reactions after Subcutaneous Bortezomib Administration in the Upper Arm in Japanese Patients with Multiple Myeloma

By  

Acta Haematologica, Vol. 133, Iss. 1, 2014-07 ,pp. : 29-30

Karger

Access to resources Recommend Favorite

Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues

By  

Oncology, Vol. 70, Iss. 6, 2007-02 ,pp. : 474-482

Karger

Access to resources Recommend Favorite